- Tags: diabetic retinopathy
Products
AEYE Health broadens Epic EMR integration for AI eye screening
Expanded deployment enables HCPs to order AEYE-DS’s portable, 1-minute diabetic retinopathy screenings without clinical workflow disruptions.
Research
Study demonstrates accuracy of new platform for comparing AI-based DR screening systems
New testing platform allows for comparison of effectiveness and fairness in commercial AI systems.
Research
Could high HDL levels lead to lower DR risk?
Study emphasizes importance of monitoring HDL levels in patients with diabetic retinopathy.
Research
GLP-1 use may lower long-term DME, DR risk
Study highlights protective effect of GLP-1 RAs against ocular complications of diabetes and disparities for racialized patients
Products
FDA approves Formycon and Bioeq's Lucentis biosimilar
Nufymco (ranibizumab-leyk) marks the companies’ second ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
Research
Does YAG capsulotomy increase DR risk?
Study highlights need for close monitoring of NPDR patients after posterior capsule opacification treatment.
Research
Could DR screenings benefit CVD detection?
Study explores potential of unexpected early advantages for patients with type 2 diabetes mellitus during routine eye exams.
Research
Clinicians are under-utilizing this AI-based DR screening system
EyeArt system demonstrates high diagnostic accuracy in detecting DR, though obstacles remain for real-world implementation.
Research
Could waist size determine DR risk?
Study demonstrates the potential of using weight-adjusted waist index to predict the risk of diabetic retinopathy.
Research
Analysis: Global DR cases on the rise, sparking urgent need for intervention
Study highlights concerning global, regional, and national trends in DR-related blindness.
Research
DR risk may significantly increase with low hemoglobin levels
New research found low levels independently increased the risk among diabetic patients—with a strong association for proliferative DR.
Research
Myopia may delay DR development and progression
Study used Mendelian randomization to identify a causal relationship between myopia and diabetic retinopathy.
Products
Regeneron receives FDA CRL, delaying Eylea HD sBLA approval
Company plans to resubmit app for pre-filled syringe version in early 2026, noting two 2025 dates to watch for.
Research
Study: DR, DME patients most likely to miss follow-up care
Multiple demographic and socioeconomic factors identified in association with loss to follow-up care in patients with PDR and DME.
Products
FDA approves Celltrion's Eylea bisoimilar
EYDENZELT (aflibercept-bvoa) is indicated for patients with wet AMD, macular edema following RVO, DME, and DR.Pipeline
FDA extends review period for EYLEA HD expanded labeling
Delay follows a recent site inspection; proposed expansion includes a new indication, updated dosings for current indications, and a pre-filled syringe version.
Research
Prevent Blindness launches diabetes and the eye advisory committee
In partnership with industry professionals, nonprofit seeks to increase awareness and early identification of diabetes-related eye diseases through three key initiatives.
Pipeline
FDA agrees to SPA for Ocular Therapeutix NPDR registrational trial
Agreement includes planned design for study evaluating AXPAXLI (formerly OTX-TIKI), an IVT implant with the potential for long-term durability and fewer injections.
Research
Study: ERG outperforms structural testing for DR risk assessment
Longitudinal research evaluates three forms of structural testing versus LKC Technologies’ RETeval in identifying high-risk patients for DR progression.
Research